Patient/Advocate Diane Redington and Dr. Whitfield Growden discuss availability, eligibility and decisions regarding clinical trials and the differences in treatment options. This is part six of a nine part series. Dr. Growden explains that carcinosarcomas are generally excluded from clinical trials, although uterine carcinosarcoma has been allowed in some trials. Soon, they are going to […]
Patient/Advocate Diane Redington and Dr. Whitfield Growden discuss genomic analysis, patterns of resistance, and immunotherapy. This is part five of a nine part series. Dr. Growden discusses tumor specimens used for genomic analysis and the impact of tumor changes. Recognizing patterns of resistance is very important for treatment. Also discussed is a type of immunotherapy […]
Patient/advocate Diane Redington and Dr. Whitfield Growden discuss the management of ovarian and uterine carcinosarcoma. This is part four of a nine part series. Dr. Growden discusses important differences between ovarian and uterine carcinosarcoma and takes us through the stages of ovarian and uterine carcinosarcoma cancers and treatment modalities for each at the various stages. […]
Patient/advocate Diane Redington and Dr. Whitfield Growden discuss current scientific findings and clinical trials in ovarian and uterine carcinosarcoma. This is part three of a nine part series. Dr. Growden discusses how they have examined tumors (from Mass General’s tumor bank) of the fallopian tubes, ovary, uterus, and vagina. They found approximately 150 different mutations […]
The second of two interviews conducted on January 5, 2017, with Diane Redington and Dr. Growdon on the topic of carcinosarcoma. This interview discusses: genomic analysis of carcinosarcoma, patterns of resistance, immunotherapy and clinical trials.
The following transcript is from an interview between Dr. Whitfield Growdon (MDC), a leading GYN Oncological Surgeon from Mass General Cancer Center in Boston and Diane Redington (DR), a woman with a Gynecological Carcinosarcoma (GCS) who is seeking to motivate researchers to advance the science and uncover knowledge about carcinosarcoma and find a cure for this cancer. This interview discusses diagnosis and treatment of MMMT.